Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASH 2022 | Exploratory analysis of the CLARITY study: ibrutinib plus venetoclax in patients with R/R CLL

Talha Munir, MBBS, Leeds Teaching Hospitals NHS Trust, Leeds, UK, shares some results from an exploratory analysis of the Phase II CLARITY study (ISRCTN13751862), which is assessing the efficacy of ibrutinib plus venetoclax in patients with relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL). Dr Munir highlights the progression-free and overall survival (PFS; OS) data and the value of early measurable residual disease (MRD) eradication in this patient population. This interview took place at the 64th ASH Annual Meeting and Exposition congress in New Orleans, LA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Disclosures

Janssen, AstraZeneca, Alexion, Sobi, Novartis, Roche, Abbvie, Gilead: Honoraria; Janssen, AstraZeneca, Alexion, Abbvie, Novartis, Roche: Membership on an entity’s Board of Directors or advisory committees.